Showing results (411-420 of 635) with videos related to
Sort By:
Pageof 64
Frontiers in Oncology|July 16, 2021
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung CancerLea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, et al.Hepatology (Baltimore, Md.)|January 8, 2019
Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic CholangiocarcinomaBenjamin Goeppert, Reka Toth, Stephan Singer, et al.Cancers|April 29, 2020
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 InhibitorsStephan Rheinheimer, Claus-Peter Heussel, Philipp Mayer, et al.Oncotarget|June 19, 2014
Potential clinical implications of BRAF mutations in histiocytic proliferationsAnna-Maria Bubolz, Stephanie E Weissinger, Albrecht Stenzinger, et al.Scientific Reports|November 13, 2023
Addressing image misalignments in multi-parametric prostate MRI for enhanced computer-aided diagnosis of prostate cancerBalint Kovacs, Nils Netzer, Michael Baumgartner, et al.Journal of Hepatology|May 28, 2013
Autophagy-enhancing drug carbamazepine diminishes hepatocellular death in fibrinogen storage diseaseFlorian Puls, Imeke Goldschmidt, Heike Bantel, et al.Acta Neuropathologica Communications|October 19, 2019
The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomasArne Christians, Antonia Adel-Horowski, Rouzbeh Banan, et al.The Journal of Pathology. Clinical Research|May 1, 2020
Endometrial stromal sarcomas with BCOR-rearrangement harbor MDM2 amplificationsFelix Kf Kommoss, Kenneth Te Chang, Damian Stichel, et al.BMC Medicine|October 24, 2022
Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boardsDamian T Rieke, Till de Bortoli, Peter Horak, et al.The Journal of Pathology. Clinical Research|January 29, 2024
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitorsMichael Menzel, Martina Kirchner, Klaus Kluck, et al.Pageof 64